1. Home
  2. APLM vs OTRK Comparison

APLM vs OTRK Comparison

Compare APLM & OTRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • APLM
  • OTRK
  • Stock Information
  • Founded
  • APLM 2016
  • OTRK 2003
  • Country
  • APLM United States
  • OTRK United States
  • Employees
  • APLM N/A
  • OTRK N/A
  • Industry
  • APLM Blank Checks
  • OTRK Misc Health and Biotechnology Services
  • Sector
  • APLM Finance
  • OTRK Health Care
  • Exchange
  • APLM Nasdaq
  • OTRK Nasdaq
  • Market Cap
  • APLM 6.5M
  • OTRK 6.1M
  • IPO Year
  • APLM N/A
  • OTRK N/A
  • Fundamental
  • Price
  • APLM $5.68
  • OTRK $1.64
  • Analyst Decision
  • APLM Strong Buy
  • OTRK Strong Buy
  • Analyst Count
  • APLM 1
  • OTRK 1
  • Target Price
  • APLM $200.00
  • OTRK $45.00
  • AVG Volume (30 Days)
  • APLM 25.0K
  • OTRK 19.0K
  • Earning Date
  • APLM 04-03-2025
  • OTRK 05-16-2025
  • Dividend Yield
  • APLM N/A
  • OTRK N/A
  • EPS Growth
  • APLM N/A
  • OTRK N/A
  • EPS
  • APLM N/A
  • OTRK N/A
  • Revenue
  • APLM $198,000.00
  • OTRK $10,846,000.00
  • Revenue This Year
  • APLM $415.15
  • OTRK $50.12
  • Revenue Next Year
  • APLM N/A
  • OTRK $55.26
  • P/E Ratio
  • APLM N/A
  • OTRK N/A
  • Revenue Growth
  • APLM N/A
  • OTRK N/A
  • 52 Week Low
  • APLM $4.71
  • OTRK $1.27
  • 52 Week High
  • APLM $42.00
  • OTRK $5.53
  • Technical
  • Relative Strength Index (RSI)
  • APLM 40.12
  • OTRK 58.85
  • Support Level
  • APLM $5.90
  • OTRK $1.46
  • Resistance Level
  • APLM $6.88
  • OTRK $1.53
  • Average True Range (ATR)
  • APLM 0.60
  • OTRK 0.10
  • MACD
  • APLM 0.01
  • OTRK 0.01
  • Stochastic Oscillator
  • APLM 13.17
  • OTRK 84.00

About APLM Apollomics Inc.

Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.

About OTRK Ontrak Inc.

Ontrak Inc is an artificial intelligence (AI)-powered and technology-enabled behavioral healthcare company, whose mission is to help improve the health and save the lives of as many people as possible. The group provides a value-based behavioral healthcare company that identifies and engages people with unmet health needs using the proprietary Advanced Engagement System to improve clinical outcomes and reduce total cost of care. The company's integrated, technology-enabled OntrakTM solutions, a component of the PRE platform, are designed to treat members with behavioral conditions that cause chronic medical conditions such as diabetes, hypertension, coronary artery disease, COPD, and congestive heart failure.

Share on Social Networks: